Original Report

BRCA1/2 testing and cancer risk management in underserved women at a public hospital


 

Background and objective Genetic test uptake and cancer risk management have been understudied in medically underserved populations. Study aims were to quantify rates of BRCA1/2 genetic testing and evidence-based cancer risk management (ie, prophylactic surgeries and surveillance practices) in women who were seen for breast and ovarian cancer genetic counseling in a public, safety net health system.

Methods We conducted a retrospective medical record abstraction of 195 women who presented for breast or ovarian genetic counseling within a 2-year period (2008-2009) at Parkland Health & Hospital System in Dallas, Texas.

Results The identified women represented a racially and ethnically diverse population: 48% Hispanic, 37% non-Hispanic black, 12% non-Hispanic white, and 3% Asian. Among the 158 women who were medically eligible for genetic testing, 134 (84.8%) received BRCA1/2 results, with most tests funded through a financial assistance program. In all, 29 women (22%) tested positive for BRCA1/2 mutations. Financial and funding barriers were identified for 20 of the untested women. Among the identified high-risk women (mutation carriers, selected variants, and noncarriers with pretest BRCAPRO scores 30 or more), 26% had prophylactic breast surgeries and 33% had prophylactic ovarian surgeries within the follow-up period averaging 35 months. Of those who opted for surveillance, 71% had at least 1 mammogram or MRI and 38% had CA-125 tests. Trends indicated lower rates of all risk management behaviors, except for mammogram or MRI, among non-Hispanic black women.

Conclusions Within this racially and ethnically diverse sample, BRCA1/2 test uptake was high, but financial barriers were identified for nontested women. The rates of breast cancer risk management were generally comparable with other studies, but risk management for ovarian cancer was limited, especially among non-Hispanic black women. The reasons for these apparen disparities should be further explored.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Superiority of Dose-Dense Chemo Upheld for Ovarian Cancer
MDedge Hematology and Oncology
HPV DNA Test Predicts Cervical Cancer Risk for 18 Years
MDedge Hematology and Oncology
Radiation Oncologists Say Medicare Cuts Could Shutter Practices
MDedge Hematology and Oncology
Pregnancy-Related Cancers: Rise Is Largely Unrelated to Delayed Childbearing
MDedge Hematology and Oncology
Don't Screen Healthy Women for Ovarian Cancer
MDedge Hematology and Oncology
HPV Vaccine's Benefits Are Mainly Extracervical
MDedge Hematology and Oncology
Screening Guidelines for Cervical Cancer
MDedge Hematology and Oncology
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
MDedge Hematology and Oncology
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
MDedge Hematology and Oncology
ASRM: Egg Freezing No Longer 'Experimental'
MDedge Hematology and Oncology